Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH EPIDEMIOLOGIST
6.8 INTERVIEWS WITH CLINICIAN
6.9 INTERVIEWS WITH ONCOLOGIST
6.1 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.2 RESTRAINTS
8.3 OPPURTUNITY
8.4 CHALLENGE
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY GRADE
10.1 OVERVIEW
10.2 GRADE II
10.3 GRADE III
10.4 GRADE IV
10.5 OTHERS
11 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATIONS
11.2.1 BY DRUG CLASS
11.2.1.1. TEMOZOLOMIDE
11.2.1.1.1. ORAL
11.2.1.1.2. INTRAVENOUS
11.2.1.2. NITROSOUREAS DRUGS
11.2.1.2.1. CARMUSTINE
I. ORAL
II. IMPLANTABLES WAFERS
11.2.1.2.2. LOMUSTINE
11.2.1.2.3. NIMUSTINE
11.2.1.2.4. FOTEMUSTINE
11.2.1.3. CORTICOSTEROIDS
11.2.1.3.1. METHYLPREDNISOLONE
11.2.1.3.2. PREDNISONE
11.2.1.3.3. OTHERS
11.2.1.4. ANTI-EPILETICS
11.2.1.5. LEVETIRACETAM
11.2.1.6. PHENYTOIN
11.2.1.7. CARBAMAZEPINE
11.2.2 BY MODE OF THERAPY
11.2.2.1. CHEMOTHERAPY
11.2.2.2. IMMUNOTHERAPY
11.2.2.3. TARGETED THERAPY
11.2.2.4. EXPERIMENTAL THERAPIES
11.2.2.4.1. GENE THERAPY
11.2.2.4.2. STEM CELL THERAPY
11.2.2.5. OTHERS
11.2.3 BY DRUG TYPE
11.2.3.1. BRANDED
11.2.3.1.1. KEPPRA
11.2.3.1.2. DILANTIN
11.2.3.1.3. TEGRETOL
11.2.3.1.4. TEMODAR
11.2.3.2. GENERICS
11.2.4 BY ROUTE OF ADMINISTRATION
11.2.4.1. ORAL
11.2.4.1.1. TABLETS
11.2.4.1.2. CAPSULES
11.2.4.1.3. POWDERS
11.2.4.2. PARENTERAL
11.2.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
11.2.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
11.2.4.3. OTHERS
11.3 RADIOTHERAPY
11.3.1 EXTERNAL BEAM RADIATION
11.3.1.1. INTENSITY-MODULATED RADIATION THERAPY (IMRT)
11.3.1.2. PROTON BEAM THERAPY
11.3.1.3. STEREOTACTIC RADIOSURGERY (E.G., GAMMA KNIFE)
11.3.2 INTERNAL RADIATION (BRACHYTHERAPY)
11.4 SURGERY TREATMENT
11.5 OTHERS
12 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 CHILD
12.3 ADULT
12.3.1 MALE
12.3.2 FEMALE
12.4 GERIATRIC
12.4.1 MALE
12.4.2 FEMALE
13 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 ONLINE
14.3.2 OFFLINE
14.4 OTHERS
15 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY GEOGRAPHY
16.1 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.1.1. U.S GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY GRADE
16.2.1.2. U.S GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT
16.2.1.3. U.S GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE
16.2.1.4. U.S GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER
16.2.1.5. U.S GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K.
16.3.4 HUNGARY
16.3.5 LITHUANIA
16.3.6 AUSTRIA
16.3.7 IRELAND
16.3.8 NORWAY
16.3.9 POLAND
16.3.10 ITALY
16.3.11 SPAIN
16.3.12 RUSSIA
16.3.13 TURKEY
16.3.14 NETHERLANDS
16.3.15 SWITZERLAND
16.3.16 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 SOUTH KOREA
16.4.4 INDIA
16.4.5 AUSTRALIA
16.4.6 SINGAPORE
16.4.7 THAILAND
16.4.8 MALAYSIA
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 VIETNAM
16.4.12 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 PERU
16.5.4 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 GLOBAL
16.6.3 UAE
16.6.4 EGYPT
16.6.5 KUWAIT
16.6.6 ISRAEL
16.6.7 REST OF MIDDLE EAST AND AFRICA
16.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
19 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, COMPANY PROFILE
19.1 GLAXOSMITHKLINE PLC.
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 ASTRAZENECA
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 F. HOFFMAN-LA ROCHE, LTD.
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 PFIZER, INC.
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MERCK & CO., INC.
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 VASCULAR BIOGENEICS
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENTS
19.7 ANGIOCHEM, INC.
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPMENTS
19.8 BOEHRINGER INGELHEIM GMBH
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPEMENTS
19.9 BRISTOL-MYERS SQUIBB COMPANY
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPEMENTS
19.1 BOSTON BIOMEDICAL
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPEMENTS
19.11 CANTEX PHARMACEUTICALS, INC.
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPEMENTS
19.12 CAVION LLC
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPEMENTS
19.13 COHERUS BIOSCIENCES, INC.
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPEMENTS
19.14 EISAI
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPEMENTS
19.15 ELI LILLY AND COMPANY
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPEMENTS
19.16 CORTICE BIOSCIENCES, INC.
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPEMENTS
19.17 ENGENEIC LTD.
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPEMENTS
19.18 GENSPERA, INC.
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPEMENTS
19.19 ERC BELGIUM SA
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPEMENTS
19.2 GENZYME CORPORATION
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPEMENTS
19.21 IMMUNOCELLULAR THERAPEUTICS, LTD.
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPEMENTS
19.22 GW PHARMACEUTICALS PLC
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPEMENTS
19.23 ACCORD HEALTHCARE POLSKA
19.23.1 COMPANY OVERVIEW
19.23.2 REVENUE ANALYSIS
19.23.3 GEOGRAPHIC PRESENCE
19.23.4 PRODUCT PORTFOLIO
19.23.5 RECENT DEVELOPEMENTS
19.24 SUN PHARMACEUTICAL LTD
19.24.1 COMPANY OVERVIEW
19.24.2 REVENUE ANALYSIS
19.24.3 GEOGRAPHIC PRESENCE
19.24.4 PRODUCT PORTFOLIO
19.24.5 RECENT DEVELOPMENTS
19.25 ANI PHARMACEUTICALS, INC.
19.25.1 COMPANY OVERVIEW
19.25.2 REVENUE ANALYSIS
19.25.3 GEOGRAPHIC PRESENCE
19.25.4 PRODUCT PORTFOLIO
19.25.5 RECENT DEVELOPMENTS
19.26 AMNEAL PHARMACEUTICALS LL
19.26.1 COMPANY OVERVIEW
19.26.2 REVENUE ANALYSIS
19.26.3 GEOGRAPHIC PRESENCE
19.26.4 PRODUCT PORTFOLIO
19.26.5 RECENT DEVELOPMENTS
19.27 MYLAN
19.27.1 COMPANY OVERVIEW
19.27.2 REVENUE ANALYSIS
19.27.3 GEOGRAPHIC PRESENCE
19.27.4 PRODUCT PORTFOLIO
19.27.5 RECENT DEVELOPMENTS
19.28 ZYDUS PHARMS
19.28.1 COMPANY OVERVIEW
19.28.2 REVENUE ANALYSIS
19.28.3 GEOGRAPHIC PRESENCE
19.28.4 PRODUCT PORTFOLIO
19.28.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
20 RELATED REPORTS
21 CONCLUSION
22 QUESTIONNAIRE
23 ABOUT DATA BRIDGE MARKET RESEARCH
